pedmark

Generic: sodium thiosulfate

pedmark: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
FENNEC PHARMACEUTICALS INC. (FENC)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Limitations of Use The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already o(FENC)

Frequently asked questions

Who is developing pedmark?

pedmark is being developed by FENNEC PHARMACEUTICALS INC..

What is pedmark's latest FDA decision?

The most recent tracked FDA decision for pedmark is Approval for 1 INDICATIONS AND USAGE PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Limitations of Use The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already o, dated September 20, 2022.

Get deeper analysis on pedmark

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    pedmark — Drug Pipeline, Trials & FDA Status | BioSniper